The usual treatment for patients with this type of lung cancer is chemotherapy with or without radiotherapy.
In this study, we want to investigate whether immunotherapy administered at the same time as standard therapy helps to stop the growth of lung cancer.
Aim of the study
In this clinical trial, we want to find out whether immunotherapy administered at the same time as standard therapy helps to stop the growth of lung cancer. The standard therapy consists of chemotherapy and radiotherapy of the metastases, followed by radiotherapy or surgery of the lung cancer. In addition, we would like to determine whether the side effects of this combination treatment are tolerable.
Who can take part?
This clinical trial is for people with lung cancer called non-small cell lung cancer (NSCLC) that has spread to a small number of other parts of the body (also called "oligometastatic lung cancer").
Procedure
If you decide to take part in this study, you will receive the following treatments:
- Radiotherapy (stereotactic body radiotherapy, SBRT) of all metastases
- Chemotherapy
- Immunotherapy (durvalumab plus tremelimumab)
If your lung cancer has remained stable, you will continue to receive the following treatments:
- Either radiotherapy or surgery for lung cancer
- Continuation of immunotherapy (durvalumab plus an additional dose of tremelimumab)
As long as you are receiving treatment, you must visit the hospital every 4 weeks. After the end of the study treatment, you will visit your doctor every 3 months. A total of up to 25 study visits can take place over a period of 1 to 2.5 years.
Compensation
none
Original study name
CHESS: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
BASEC number
2019-01234
Financial support from
ETOP IBCSG